Glenmark Pharmaceuticals on Tuesday said it has received final approval from the United States Food & Drug Administration (USFDA) for Deferasirox tablets for oral suspension, 125 mg, 250 mg and 500 mg, the generic version of exjade tablets of Novartis Pharmaceuticals Corporation, the company said in a filing to the stock exchanges. The tablet is used to treat high levels of iron in the body caused by multiple blood transfusions. According to IQVIA sales data for the 12-month period ending November 2019, exjade tablets had annual sales of approximately $106.4 million (about ₹750 crore). Shares of Glenmark Pharma closed at ₹343.15, up 1.03 per cent, on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.